NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $358.60 -8.76 (-2.38%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About United Therapeutics Stock (NASDAQ:UTHR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get United Therapeutics alerts:Sign Up Key Stats Today's Range$356.13▼$369.0050-Day Range$345.64▼$380.7852-Week Range$214.75▼$417.82Volume190,929 shsAverage Volume340,463 shsMarket Capitalization$16.01 billionP/E Ratio15.75Dividend YieldN/APrice Target$382.08Consensus RatingModerate Buy Company OverviewUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More… United Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreUTHR MarketRank™: United Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 127th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageUnited Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth11.43% Earnings GrowthEarnings for United Therapeutics are expected to grow by 11.43% in the coming year, from $25.11 to $27.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 16.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.35.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 16.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.93.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 0.99. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.59% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in United Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-2.00 Percentage of Shares Shorted4.59% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in United Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing. News and Social Media3.8 / 5News Sentiment0.82 News SentimentUnited Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for United Therapeutics this week, compared to 11 articles on an average week.Search Interest15 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows9 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,227,465.00 in company stock.Percentage Held by Insiders11.90% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock News HeadlinesMichael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockFebruary 20 at 4:57 AM | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives $382.08 Consensus PT from BrokeragesFebruary 21 at 1:47 AM | americanbankingnews.comMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.February 21, 2025 | Colonial Metals (Ad)United Therapeutics Corp (UTHR) to Announce Q4 and Full Year 2024 Financial ResultsFebruary 20 at 10:34 AM | gurufocus.comQ4 EPS Estimate for United Therapeutics Reduced by AnalystFebruary 15, 2025 | americanbankingnews.comUnited Therapeutics: Growth Prospects and Financial Performance Support ‘Buy’ RatingFebruary 13, 2025 | tipranks.comUnited Therapeutics Corporation (UTHR): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | insidermonkey.comUnited Therapeutics' president sells shares worth $3.48 millionFebruary 11, 2025 | msn.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $352.84 at the beginning of the year. Since then, UTHR shares have increased by 3.3% and is now trading at $364.3850. View the best growth stocks for 2025 here. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. The company's quarterly revenue was up 22.9% compared to the same quarter last year. Who are United Therapeutics' major shareholders? United Therapeutics' top institutional shareholders include Wealthfront Advisers LLC (41.02%), Vanguard Group Inc. (9.95%), Avoro Capital Advisors LLC (6.18%) and Wellington Management Group LLP (5.52%). Insiders that own company stock include Paul A Mahon, James Edgemond, Judy D Olian, Nilda Mesa, Louis W Sullivan, Christopher Causey, Michael Benkowitz, Raymond Dwek, Martine A Rothblatt and Christopher Patusky. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings10/30/2024Today2/21/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$382.08 High Stock Price Target$600.00 Low Stock Price Target$280.00 Potential Upside/Downside+6.2%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$22.77 Trailing P/E Ratio15.81 Forward P/E Ratio14.33 P/E Growth0.99Net Income$984.80 million Net Margins40.31% Pretax Margin52.17% Return on Equity19.22% Return on Assets16.15% Debt Debt-to-Equity RatioN/A Current Ratio4.58 Quick Ratio4.41 Sales & Book Value Annual Sales$2.33 billion Price / Sales6.90 Cash Flow$20.87 per share Price / Cash Flow17.24 Book Value$127.35 per share Price / Book2.82Miscellaneous Outstanding Shares44,650,000Free Float39,332,000Market Cap$16.06 billion OptionableOptionable Beta0.57 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:UTHR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.